InvestorsObserver
×
News Home

Where Does Biogen Inc (BIIB) Stock Fall in the Drug Manufacturers - General Field After It Is Down -0.32% This Week?

Tuesday, September 21, 2021 02:16 PM | InvestorsObserver Analysts

Mentioned in this article

Where Does Biogen Inc (BIIB) Stock Fall in the Drug Manufacturers - General Field After It Is Down -0.32% This Week?

Biogen Inc (BIIB) is around the top of the Drug Manufacturers - General industry according to InvestorsObserver. BIIB received an overall rating of 58, which means that it scores higher than 58 percent of all stocks. Biogen Inc also achieved a score of 86 in the Drug Manufacturers - General industry, putting it above 86 percent of Drug Manufacturers - General stocks. Drug Manufacturers - General is ranked 97 out of the 148 industries.

Overall Score - 58
BIIB has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on BIIB!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 58 means the stock is more attractive than 58 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Biogen Inc Stock Today?

Biogen Inc (BIIB) stock is down -1.17% while the S&P 500 is up 0.13% as of 2:10 PM on Tuesday, Sep 21. BIIB has fallen -$3.49 from the previous closing price of $298.49 on volume of 456,181 shares. Over the past year the S&P 500 has risen 32.98% while BIIB is up 9.95%. BIIB earned $12.47 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 23.66. Click Here to get the full Stock Report for Biogen Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App